The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

被引：25

作者：

Stoian, Anca Pantea ^{[1
]}

Sachinidis, Alexandros ^{[2
,3
]}

Stoica, Roxana Adriana ^{[1
]}

Nikolic, Dragana ^{[2
]}

Patti, Angelo Maria ^{[2
]}

Rizvi, Ali A. ^{[4
]}

机构：

[1] Carol Davila Univ Med & Pharm, Dept Diabet Nutr & Metab Dis, Bucharest, Romania

[2] Univ Palermo, PROMISE Dept, Sch Med, Palermo, Italy

[3] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Sch Med, Thessaloniki, Greece

[4] Emory Univ, Div Endocrinol Metab & Lipids, Sch Med, Atlanta, GA 30322 USA

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 109卷

关键词：

INCRETIN-BASED THERAPIES; MAJOR CARDIOVASCULAR EVENTS; GLUCAGON-LIKE PEPTIDE-1; ADD-ON THERAPY; DPP-4; INHIBITORS; ACUTE-PANCREATITIS; HEART-FAILURE; COMBINATION THERAPY; AMERICAN-COLLEGE; POSITION STATEMENT;

D O I：

10.1016/j.metabol.2020.154295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based-medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective: This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discussion: DPP4is are moderately efficient in decreasing the HbA1c by an average of 0.5% as monotherapy, and 1.0% in combination therapy with other drugs. They have a good tolerability and safety profile compared to other glucose-lowering drugs. However, there are possible risks pertaining to acute pancreatitis and pancreatic cancer. Conclusion: Cardiovascular outcome trials thus far have proven the cardiovascular safety for ischemic events in patients treated with sitagliptin, saxagliptin, alogliptin, linagliptin and vildagliptin. Data showing increased rate of hospitalisation in the case of saxagliptin did not seem to be a class effect. (C) 2020 Published by Elsevier Inc.

引用

页数：8

共 129 条

[11] Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis [J].

Azoulay, Laurent ;

Filion, Kristian B. ;

Platt, Robert W. ;

Dahl, Matthew ;

Dormuth, Colin R. ;

Clemens, Kristin K. ;

Durand, Madeleine ;

Hu, Nianping ;

Juurlink, David N. ;

Paterson, J. Michael ;

Targownik, Laura E. ;

Turin, Tanvir C. ;

Ernst, Pierre .

JAMA INTERNAL MEDICINE, 2016, 176 (10) :1464-1473

[12] Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes [J].

Bailey, Clifford J. ;

Del Prato, Stefano ;

Wei, Cheryl ;

Reyner, Daniel ;

Saraiva, Gabriela .

DIABETES OBESITY & METABOLISM, 2019, 21 (11) :2564-2569

[13] Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis [J].

Barkas, F. ;

Elisaf, M. ;

Tsimihodimos, V. ;

Milionis, H. .

DIABETES & METABOLISM, 2017, 43 (01) :1-8

[14] Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial [J].

Barzilai, Nir ;

Guo, Hua ;

Mahoney, Erin M. ;

Caporossi, Suzanne ;

Golm, Gregory T. ;

Langdon, Ronald B. ;

Williams-Herman, Debora ;

Kaufman, Keith D. ;

Amatruda, John M. ;

Goldstein, Barry J. ;

Steinberg, Helmut .

CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) :1049-1058

[15] Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes [J].

Bekiari, Eleni ;

Rizava, Chrysoula ;

Athanasiadou, Eleni ;

Papatheodorou, Konstantinos ;

Liakos, Aris ;

Karagiannis, Thomas ;

Mainou, Maria ;

Rika, Maria ;

Boura, Panagiota ;

Tsapas, Apostolos .

ENDOCRINE, 2016, 52 (03) :458-480

[16] Progression of glucose-lowering diabetes therapy in TECOS [J].

Bethel, M. Angelyn ;

Engel, Samuel S. ;

Stevens, Susanna R. ;

Lokhnygina, Yuliya ;

Ding, Jie ;

Josse, Robert G. ;

Alvarsson, Michael ;

Hramiak, Irene ;

Green, Jennifer B. ;

Peterson, Eric D. ;

Holman, Rury R. .

ENDOCRINOLOGY DIABETES & METABOLISM, 2019, 2 (01)

[17] Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [J].

Bethel, M. Angelyn ;

Engel, Samuel S. ;

Green, Jennifer B. ;

Huang, Zhen ;

Josse, Robert G. ;

Kaufman, Keith D. ;

Standl, Eberhard ;

Suryawanshi, Shailaja ;

Van de Werf, Frans ;

McGuire, Darren K. ;

Peterson, Eric D. ;

Holman, Rury R. .

DIABETES CARE, 2017, 40 (04) :494-501

[18] Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities [J].

Brown, Emily ;

Wilding, John P. H. ;

Barber, Thomas M. ;

Alam, Uazman ;

Cuthbertson, Daniel J. .

OBESITY REVIEWS, 2019, 20 (06) :816-828

[19] Pancreatic Safety of Sitagliptin in the TECOS Study [J].

Buse, John B. ;

Bethel, M. Angelyn ;

Green, Jennifer B. ;

Stevens, Susanna R. ;

Lokhnygina, Yuliya ;

Aschner, Pablo ;

Grado, Carlos Raffo ;

Tankova, Tsvetalina ;

Wainstein, Julio ;

Josse, Robert ;

Lachin, John M. ;

Engel, Samuel S. ;

Patel, Keyur ;

Peterson, Eric D. ;

Holman, Rury R. .

DIABETES CARE, 2017, 40 (02) :164-170

[20] Emerging gliptins for type 2 diabetes [J].

Cahn, Avivit ;

Raz, Itamar .

EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (02) :245-258

← 1 2 3 4 5 6 7 8 9 10 →